Literature DB >> 2528037

Coronary atherectomy: first 50 patients at the Mayo Clinic.

U P Kaufmann1, K N Garratt, R E Vlietstra, K K Menke, D R Holmes.   

Abstract

The safety and efficacy of a novel coronary atherectomy device were evaluated in the first 50 patients who underwent 53 such procedures at the Mayo Clinic. This treatment was used for atheromatous lesions in 27 patients and for restenosis after percutaneous transluminal coronary angioplasty in 23; in 3 patients, it was repeated for recurrent stenosis (2) or a persistent intimal flap (1). Successful results, defined as a reduction of the stenosis by 40% or more in association with removal of tissue, absence of Q-wave infarction, and no need for a bypass surgical procedure during in-hospital follow-up, were achieved in 47 of the 53 procedures (89%). Atherectomy reduced the stenoses from a mean of 87% to 15%. Failures occurred in 6 of the 53 procedures (11%). Three of these patients subsequently underwent successful conventional balloon angioplasty, and three required surgical treatment. Six patients had minor complications--embolization of atheromatous material in two, intimal dissection in two, and side-branch occlusion and transient thrombosis in one each. Coronary atherectomy with use of this device promises to be a relatively safe and efficient treatment of coronary artery stenosis.

Entities:  

Mesh:

Year:  1989        PMID: 2528037     DOI: 10.1016/s0025-6196(12)61745-5

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  2 in total

1.  Animal evaluation of the prototype omnicath atherectomy catheter.

Authors:  M R Sapoval; J C Gaux; P Bruneval; P Peronneau
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Jul-Aug       Impact factor: 2.740

2.  Histopathological examination of specimens removed during directional coronary atherectomy in patients presenting with crescendo angina show mural thrombus.

Authors:  C M Bellamy; E D Grech; M T Ashworth; D R Ramsdale
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.